What is the potential of #digital technologies to improve the assessment of #Alzheimer’s disease?RADAR-AD videos provide the answer and expain its research, preliminary results and patient experiences with the project: https://t.co/5vrjZdAOOF @IHIEurope @AlzheimerEurope @KCL_OAP

A recent RADAR-AD consortium publication sheds light on the #ethical challenges of using remote monitoring technologies (#RMTs) for #clinical research. Find out more here: https://t.co/OV1M2FYSXJ @AlzheimerEurope @IHIEurope @KCL_OAP @KingsCollegeLon @amsterdamumc @JanssenGlobal

On June 9th, the Alzheimer center at @amsterdamumc held a participant day for RADAR-AD study participants. RADAR-AD researchers discussed developments in #Alzheimer’s research and presented RADAR-AD results: https://t.co/lpF9dvNijn @ARK_KCL @AlzheimerEurope @IHIEurope

RADAR-AD paper investigates the value of #RMTs in the assessment of #neurodegenerative conditions, their usability and feasibility and the learnings from the project’s #public involvement and #regulatory interactions: https://t.co/0dDdw72vNP @AlzheimerEurope @IHIEurope @KCL_OAP

On the 5th of June, the RADAR-AD consortium met with the European Medicines Agency (@EMA_News) to seek qualification advice on its research and use of #digital devices for future studies concerning medicine development. Find out more here: https://t.co/VbGpxWCtFq

A recent RADAR-AD study investigated the effect of meditation practices on the human brain across the #Alzheimer spectrum by using a novel portable #EEG headband in a #smarthome environment. Find out more: https://t.co/dDdIVCGRU5 @CERTHellas

The RADAR-AD consortium celebrates 4 years of research and achievements in a close-out project meeting and a public event that took place in Amsterdam, on the 15th and 16th of May: https://t.co/hOns2jjuzP @AlzheimerEurope @IHIEurope @ARK_KCL @KCL_OAP

🚨 Register for the @radar_base Symposium 2023 for free! https://t.co/Bore6xBQns This second edition of the RADAR-base Symposium is dedicated to exploring the latest developments in the field of Mobile Health #symposium #wearables @IHIEurope @RADARAD7

Join RADAR-AD's public event on the 16th May in Amsterdam in which we will explain our work, showcase the results from our studies and discuss plans for the exploitation and sustainability of our achievements! Explore the program, speakers and our research https://t.co/WYXuyjiCN5

On the 14th of March, RADAR-AD investigators finalized the data set of the main study with data collected from 232 study participants. During the 8-week data collection period, researchers measured participants’ functioning in daily life. More: https://t.co/WpgKcqQDCn @IHIEurope

Registrations are now open! Reserve your spot at the upcoming 2nd RADAR-base Symposium taking place in Utrecht, Netherlands. ✏️ Sign up here: https://t.co/Bore6xCod0 @radar_base @RADARAD7 @phidatalab @IHIEurope #radarbase #wearables #opensource #conference #Utrecht

IMI projects @RADARAD7, @RADARCNS, @ideafastproject @Mobilise_D are showing how smartphones and wearable devices can help understand how patients with different brain diseases experience their conditions in their everyday lives. #BAW2023 #BrainAwarenessWeek

Happy new year from the RADAR-AD team! Check out our latest newsletter featuring updates from the RADAR-AD project and plans for the last 6 months of activities: https://t.co/FXlcdTjgtE @IMI2_NEURONET @AlzheimerEurope @ARK_KCL @IHIEurope

Last week, @mason4233, member of the RADAR-AD Patient Advisory Board, shared his experience of patient involvement in dementia research at the @EFPIA workshop “Enhancing #patientcentric outcome measures and clinical trials with Digital Health Technologies”: https://t.co/S3hkaX10BG

Last week Prof. Dr. @frohlich_holger (@fraunhofer_scai), leading RADAR-AD’s work stream on functional domains and modelling, gave a talk on the project at the Luxembourg Centre for Systems Biomedicine. Find out more about this presentation here: https://t.co/opwtSvekxJ

On the 30 Nov, RADAR-AD's participating clinical center in Geneva (Switzerland) included the 220th and final participant in the RADAR-AD study. This represents a significant milestone for the RADAR-AD clinical trial: https://t.co/oB3FghIQDp @KCL_OAP @AlzheimerAms @KingsCollegeLon

Last month RADAR-AD was represented at the European Digital Medicine Conference. Prof. Dr. @frohlich_holger (@fraunhofer_scai), Group leader AI & data science and deputy head of bioinformatics, spoke about RADAR-AD's functional domains and modelling work: https://t.co/dS4Xs5BVX6

RADAR-AD researcher @IouliettaLazar1 from the @CERTHellas spoke at the 32nd Alzheimer Europe conference “Building bridges” (#32AEC). She presented the reserach and experiences of RADAR-AD's smart home study. Read on here: https://t.co/qcrrIvntM4

The fourth RADAR-AD consortium meeting took place as a hybrid event on the 28th and 29th of September in Amsterdam, The Netherlands. Read more about the discussions, patient involvement talk and keynote speakers here: https://t.co/52nCzHiBrE @IHI @AlzheimerEurope @IMI2_NEURONET

.@EisaiUS and @biogen announced top-line results from the Phase III #clinicaltrial Clarity AD of #lecanemab in early #Alzheimer’s disease. Primary endpoint and all key secondary endpoints were met. We look forward to hearing more at #CTAD22 https://t.co/PpcYARiQp1